SK biopharmaceuticals Co., Ltd.
KOSPI-listed drugmaker behind epilepsy treatment cenobamate (XCOPRI) and sleep disorder drug solriamfetol (SUNOSI).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2011 and listed on KOSPI in 2020, SK Biopharmaceuticals is a drug developer focused on central nervous system disorders, with SK Group's drug R&D dating back to 1993. It holds the self-developed epilepsy treatment cenobamate (marketed as XCOPRI in the US and ONTOZRY in Europe) and the out-licensed sleep disorder drug solriamfetol (marketed as SUNOSI in the US), and has signed cenobamate license-out agreements with partners including Angelini Pharma, Ono Pharmaceutical, and Knight Therapeutics. Consolidated 2025 revenue was KRW 706.7 billion, with cenobamate contributing KRW 683.0 billion (96.7%) and solriamfetol KRW 11.4 billion (1.6%); the company also secured targeted protein degradation (TPD) technology through its acquisition of SK Lifescience Labs (formerly ProteoVant) and entered the radiopharmaceutical therapy (RPT) field with candidates SKL35501 and SKL37321.
Products & technology
- CenobamateEpilepsy treatment
- SolriamfetolSleep disorder (narcolepsy, etc.) treatment
Clinical trials
data.go.kr9 MFDS clinical trial authorisations · 2018–2026 (Phase 3 5 · Phase 1 4)
- Phase 1SKL35501 주2026-01-29
3 trial sites
- Phase 1YKP3089 정2023-12-12
4 trial sites
- Phase 3YKP3089 정2023-08-28
5 trial sites
- Phase 3YKP3089 정2023-03-29
5 trial sites
- Phase 3카리스바메이트 (YKP509) 경구용 현탁액2022-11-10
6 trial sites
- Phase 3YKP3089 정2022-02-23
6 trial sites
- Phase 3YKP3089 정2020-09-09
14 trial sites
- Phase 1SKL20540캡슐2018-01-12
1 trial site
- Phase 1YKP3089 정2018-01-10
1 trial site
R&D and key agreements
Source: DART corporate disclosureTPD(표적단백질분해 치료제) · 항암(CNS 역량 확장) · 기술 확보 단계 · Technology acquired via acquisition of SK Lifescience Labs (formerly ProteoVant)
RPT(방사성의약품) - SKL35501, SKL37321 · 항암 · 후보물질 도입 · Radiopharmaceutical candidates introduced
카리스바메이트 · 중국 지역 개발 준비중 · Licensed to Ignis Therapeutics (Nov 11, 2021)
SKL13865 · 중국 지역 개발 준비중 · Licensed to Ignis Therapeutics (Nov 11, 2021)
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition